清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Prevalence, awareness, and treatment of chronic kidney disease among adults in Yunnan Province, China: findings from the 2023 chronic disease and risk factors surveillance

作者
Ying Shao,Yurong Fan,Jiao Gao,Haorong Meng,Meixian Wang,Qingping Shi,Yang Chen
出处
期刊:Frontiers in Public Health [Frontiers Media]
卷期号:13: 1685691-1685691
标识
DOI:10.3389/fpubh.2025.1685691
摘要

Background Based on data from the seventh China Chronic Diseases and Risk Factors Surveillance (CCDRFS) conducted in Yunnan Province in 2023, this study aimed to provide province-wide estimates of the prevalence, awareness, and treatment of chronic kidney disease (CKD) and to describe their distribution. Methods This provincial-level representative cross-sectional study included 6,231 adults sampled from 10 county- or district-level surveillance sites in Yunnan Province, Southwest China. All participants were subject to questionnaires, physical examinations, and laboratory tests. CKD-EPI equation was used to estimate glomerular filtration rate (eGFR) based on serum creatinine. Results A total of 6,231 adults with measurements of eGFR and urine albumin were included in this study. The weighted prevalence of CKD was 13.1% (95% CI: 10.9–15.6%) overall, 12.7% (95% CI: 10.1–15.8%) among males, and 13.5% (95% CI: 10.2–17.6%) among females. Higher prevalence of CKD was observed in subgroups characterized by older age, lower education levels, being divorced/widowed/separated, and the presence of comorbidities (hypertension, diabetes, and hyperuricemia). Among participants with CKD, 61.5, 34.2, 3.2, 0.7, 0.2, and 0.1% were classified into stage G1, G2, G3a, G3b, G4, and G5, respectively. Overall CKD awareness and treatment rates were 3.0% (95% CI: 1.5–5.8%) and 1.0% (95% CI: 0.4–2.2%). Among individuals aware of their CKD status, 11.5% (95%CI: 6.5–19.9%) were receiving treatment. Participants with stage G4 or G5 demonstrated higher awareness and treatment. CKD patients with comorbid hypertension had higher awareness, while underweight CKD patients had higher treatment rates. Conclusion The estimated CKD prevalence among adults in Yunnan Province in 2023 exceeded the national average (8.2%). CKD awareness and treatment rates were critically low. Targeted early screening programs or community-based interventions should be prioritized as urgent public health initiatives to improve disease recognition and treatment adherence for CKD prevention and management in China’s less developed regions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
7秒前
可爱的函函应助给好评采纳,获得10
12秒前
科研通AI2S应助darcyz采纳,获得10
16秒前
科研通AI2S应助darcyz采纳,获得10
16秒前
科研通AI2S应助darcyz采纳,获得10
16秒前
科研通AI2S应助darcyz采纳,获得10
16秒前
英姑应助darcyz采纳,获得10
16秒前
科研通AI2S应助darcyz采纳,获得10
16秒前
科研通AI2S应助darcyz采纳,获得10
16秒前
香蕉觅云应助darcyz采纳,获得10
16秒前
科研通AI2S应助darcyz采纳,获得10
16秒前
科研通AI2S应助darcyz采纳,获得10
16秒前
19秒前
鲤鱼小蕾完成签到,获得积分10
21秒前
给好评发布了新的文献求助10
23秒前
luckydog完成签到 ,获得积分10
49秒前
遗忘完成签到,获得积分10
50秒前
59秒前
霸气芫完成签到 ,获得积分10
1分钟前
zz发布了新的文献求助10
1分钟前
1分钟前
wave8013完成签到 ,获得积分10
1分钟前
1分钟前
Xiaojiu完成签到 ,获得积分10
1分钟前
六一儿童节完成签到 ,获得积分0
1分钟前
zzhui完成签到,获得积分10
1分钟前
zzzrrr完成签到 ,获得积分10
2分钟前
科研通AI2S应助zz采纳,获得10
2分钟前
2分钟前
Elytra完成签到,获得积分10
2分钟前
今天完成签到,获得积分10
2分钟前
CCC完成签到,获得积分10
2分钟前
蓬荜生辉完成签到,获得积分10
2分钟前
细心白竹完成签到 ,获得积分10
2分钟前
翟庆春完成签到,获得积分10
2分钟前
科研通AI6.3应助悠悠采纳,获得10
2分钟前
阳光的凡阳完成签到 ,获得积分10
2分钟前
哈哈哈完成签到 ,获得积分10
3分钟前
落后的怀梦完成签到 ,获得积分10
3分钟前
高分求助中
Psychopathic Traits and Quality of Prison Life 1000
Chemistry and Physics of Carbon Volume 18 800
The formation of Australian attitudes towards China, 1918-1941 660
Signals, Systems, and Signal Processing 610
天津市智库成果选编 600
Forced degradation and stability indicating LC method for Letrozole: A stress testing guide 500
全相对论原子结构与含时波包动力学的理论研究--清华大学 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6451279
求助须知:如何正确求助?哪些是违规求助? 8263209
关于积分的说明 17606337
捐赠科研通 5516011
什么是DOI,文献DOI怎么找? 2903608
邀请新用户注册赠送积分活动 1880627
关于科研通互助平台的介绍 1722627